Generalized polyneuropathyhas been reported in patients receiving DUOPA. Assess patients for the signs and symptoms of peripheral neuropathy before and periodically after starting DUOPA, especially patients with pre-existing neuropathy, patients taking medications, or those who have medical conditions associate...
Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets. US-QLP-250104 Please see full Prescribing Information. References This site is intended for U.S. healthcare professionals only. Important Safety Information Full Prescribing Information Contact Medical Information...
Learn more about SCEMBLIX® (asciminib), a treatment option for adult patients with newly diagnosed Ph+ CML-CP. See full Prescribing and Safety Information.
40% Faster Adoption with Targeted OutreachSee Q2 2024 report on the value of pre-launch scientific activity Connected Engagement Creates an EdgeRead Q1 2024 report on managing declining HCP access Better Engage HCPs with Field InsightsRead Q4 2023 report for three biopharma perspectives...
Learn more about the ILARIS Companion program, which offers helpful services and resources for your patients. See full Prescribing & Safety Information.
Please click forFull Prescribing Information. References: ENTYVIO (vedolizumab) prescribing information. Takeda Pharmaceuticals. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.Am...
Please seeaccompanyingfullPrescribing Information Indications Atopic Dermatitis:DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when...
Find HCP information on SUNLENCA® (lenacapavir), an FDA-approved antiretroviral used in combination with other medications for the treatment of multidrug-resistant HIV-1. See Important Safety Information and full Prescribing Information.
LIVALO is a moderate-intensity statin that demonstrated potent LDL-C reductions at the 4-mg dose in clinical trials. For healthcare providers.
†In Phase 4 study (N=42).1,3 Help get your patient started on TEPEZZA now Complete the PDF of the Patient Enrollment Form to get your patient started on TEPEZZA COMPLETE THE PDF Your patients may be eligible for the Amgen Commercial Co-pay Program‡ ...